Operating profit EBITDA: DBV Technologies S.A. (DBVT)

DBV Technologies S.A. (DBVT) is focusing on completing clinical trials and preparing FDA documentation for Viaskin patches. Analysis of the EBITDA_Co chart allows for tracking operating cash flow, where the 0.00 mark serves as a key metric. Growth is based on patents and epicutaneous immunotherapy for food allergies. Its status as an innovator and the trust of parents solidify the brand's role as a lifesaver for children.

Profit before payment of interest, taxes and amortization: dbv-technologies.com (DBVT) for 11/23/2025 - 11/10/2026

DBV Technologies (DBVT) - metric breakdowns and financial figures

- stock value and consensus price forecast:

Market Chart DBV Tech|DBVT - Price Target Chart

- company stock exchange capitalization indicators:

Market Capitalization DBV Technologies|DBVT - Enterprise Value

- book value of equity indicators:

Net Assets per Share DBV Technologies|DBVT - Company Book Value|Capitalization to Book Value Ratio dbv-technologies.com|DBVT - Company Total Assets

- business debt structure and liquidity details:

- company profitability and valuation multiples indicators:

DBVT - Net Profit|Expected Net Profit DBV Technologies S.A.|DBVT - P/E Multiple|Projected Price to Earnings DBV Tech|DBVT - PEG Multiple|Business Value to Operating Income Before Depreciation DBV Technologies|DBVT - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months DBV Technologies|DBVT - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months dbv-technologies.com|DBVT - Earnings per share growth in current year|Net earnings per share growth forecast for next year DBV Technologies S.A.

Fundamental company valuation:DBV Technologies S.A. (DBVT)

This indicator measures net cash flow from operating activities before interest and taxes, allowing for a real-time assessment of the business's operational efficiency. For DBV Technologies S.A. (DBVT), the absolute EBITDA level will serve as key confirmation of the Viaskin technology's commercialization following FDA approval, demonstrating the company's ability to transform patent protection and distribution into actual financial stability.

Competitor analysis for DBV Technologies S.A.

Operating income before deduction of amortization Krystal Biotech Corp. (KRYS)|APGE - Profit before payment of interest, taxes and amortization|ARQT - Operating profit EBITDA|VCEL: Operating profit EBITDA|ORKA - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Sanara MedTech, Inc.|Operating profit before amortization SLSN (Solesence Inc.)|Operating profit EBITDA DERM|fortebiorx.com - Operating profit before amortization|Operating profit EBITDA EMPG (Empro Group)|Sol-Gel Technologies Ltd - Profit before payment of interest, taxes and amortization|AXIL: Operating profit before deduction of amortization|MDCX: Profit before payment of interest, taxes and amortization|VRCA (verrica.com) - Operating profit before deduction of amortization|Hoth Therapeutics - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization BFRI|VYNE (VYNE Therapeutics Inc) - Company profit before taxes, interest and amortization|Operating profit EBITDA SNOA|QNRX - Profit before interest, taxes and amortization|Operating profit EBITDA AZTR (Azitra, Inc.)|DRMA - Operating profit before deduction of amortization|Elevai Labs - Operating profit EBITDA|Income before deduction of interest, taxes and amortization RVNC (Revance Therapeutics Inc.)